Monast (Montelukast)

Montelukast, the active ingredient in Monast, is a leukotriene receptor antagonist presented as an oral dosage form for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children as directed by a healthcare professional.

GNH USA supplies Monast as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage conditions involving airway inflammation.

- Asthma: improves long‑term control and reduces the frequency of exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: occasional discomfort. - Cough: transient irritation. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips or throat requiring urgent care. - Stevens‑Johnson syndrome: severe skin reactions. - Hepatic injury: elevated liver enzymes or jaundice. - Mood changes: rare reports of depression or suicidal thoughts.

When prescribing Montelukast, clinicians should consider several safety aspects.

- Pregnancy: Category B; use only if the benefit outweighs potential risk. - Breastfeeding: monitor infant for possible effects; benefits usually outweigh risks. - Liver impairment: dose adjustment may be needed; monitor hepatic function. - Concomitant enzyme inducers (e.g., rifampin, phenobarbital): may reduce efficacy. - Hypersensitivity: avoid in patients with known allergy to montelukast or its excipients. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced effectiveness or increased toxicity.

Major Interactions (Avoid): - Rifampin: induces metabolism, lowering montelukast plasma levels. - Phenobarbital: enzyme induction may diminish therapeutic effect. - Ketoconazole: strong CYP3A inhibition can raise montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation. - Beta‑agonists: additive bronchodilation may enhance symptom relief. - ACE inhibitors: combined use may increase cough frequency.